Supplementary
. Secondary and exploratory outcomes for the effects of fructose on postprandial carbohydrate metabolism, using the assigned 0g-fructose control in all analyses. Data reported as mean + SEM. Mean + SEM and p-values are reported for n=25. A linear mixed effect model was used to assess the differences in all outcome measures with unstructured covariance for repeated measures within subjects. *P-values were considered significant if P<0.0125, see Section 2.8. φ Values were rounded down and are not significant. θ Descriptive statistics are reported for n=25, but analysis was performed after one missing value was generated (n=24) in the log transformation of the data. ** Data are skewed but all standard transformations were unable to remedy the issue, so data analyzed in raw form. † P-values for iAUC and total AUC PI, absolute and incremental Cmax PI, absolute and incremental mean PI, ∆PI30-0/∆PG30-0, Matsuda ISIOGTT and ISSI-2 correspond to log-transformed data due to non-normal distributions of residuals. Abs, absolute; Cmax, maximum concentration; iAUC, incremental area under the curve; Inc, incremental; ISSI-2, insulin secretion-sensitivity index-2; Matsuda ISIOGTT, Matsuda whole body insulin sensitivity index; PG, plasma glucose; PI, plasma insulin; tAUC, total area under the curve; Tmax, time of maximum concentration; ∆PI30-0/∆PG30-0, early insulin secretion index. Data reported as mean + SEM. Mean + SEM and p-values are reported for n=25. A linear mixed effect model was used to assess the differences in all outcome measures with unstructured covariance for repeated measures within subjects. P-values were considered significant if P<0.0125, see Section 2.8. θ Descriptive statistics are reported for n=25, but analysis was performed after one missing value was generated (n=24) in the log transformation of the data. ** Data are skewed but all standard transformations were unable to remedy the issue, so data analyzed in raw form. † P-values for iAUC and total AUC PI, absolute and incremental Cmax PI, absolute and incremental mean PI, ∆PI30-0/∆PG30-0, Matsuda ISIOGTT and ISSI-2 correspond to log-transformed data due to non-normal distributions of residuals. Abs, absolute; Cmax, maximum concentration; iAUC, incremental area under the curve; Inc, incremental;
ISSI-2, insulin secretion-sensitivity index-2; Matsuda ISIOGTT, Matsuda whole body insulin sensitivity index; PG, plasma glucose; PI, plasma insulin; tAUC, total area under the curve; Tmax, time of maximum concentration; ∆PI30-0/∆PG30-0, early insulin secretion index. Table S3 . Self-reported adverse events showed no pattern associated with treatment type.
Participant

ID
Self-Reported Adverse Event Treatment
(dropout)
The participant e-mailed study staff and indicated that he had decided not to complete the final study visit due to symptoms (mainly fatigue, dizziness, low BP) he experienced after the last (5th) study visit. Participant now considered study drop out. 
5
Direct venous blood draw was used for the final blood sample (as the catheter failed). Afterwards, participant felt unwell and asked to lie down. Participant laid down for 5 mins and then felt okay.
5g F + 75g OGTT
6
Participant informed study staff on visit 3 that participant fainted after visit 2. Participant did not inform study staff that he had consumed 4L of Peglyte for the purposes of a colonoscopy, the night before the clinic visit. Participant was scheduled to have a colonoscopy on the afternoon after visit 2 but missed it due to the fainting episode. Incident was reported to St. Michael's Hospital REB.
75g-OGTT
A, allulose; BP, blood pressure; F, fructose; REB, research ethics board; SAE, severe adverse event; OGTT, oral glucose Figure S1 . CONSORT statement for the healthy participants in the FACE Trial.
Supplementary Figures
B. Allulose P-value for departure from linearity: 0.629 P-value for linear dose response: 0.126 P-value for linear dose response: 0.306 P-value for departure from linearity: 0.215 Figure S2 . (A) Linear (left) and non-linear dose-response (right) analysis of the effect of small doses of fructose on plasma glucose iAUC. (B) Linear (left) and non-linear (right) dose-response analysis of the effect of small doses of allulose on plasma glucose iAUC. In the linear dose-response graphs, the inner line represents the predicted linear trend, while the two outer lines represent the 95% CIs. In the non-linear dose-response graphs, the center line represents the mean, while the two outer lines represent the 95% CIs. P-values were considered significant if P<0.0125, see Section 2.8. incremental glucose (C), insulin iAUC (D), absolute Cmax insulin (E) and Tmax insulin (F). In the linear dose-response graphs, the inner line represents the predicted linear trend, while the two outer lines represent the 95% CIs. In the non-linear dose-response graphs, the center line represents the mean, while the two outer lines represent the 95% CIs. P-values correspond to log-transformed data due to non-normal distribution of residuals for (D) and (E). P-values were considered significant if P<0.0125, see Section 2.8. Figure S4 . Linear (left) and non-linear (right) dose-response analysis of the effect of small doses of fructose mean incremental insulin (A), Early Insulin Secretion Index (∆PI30-0/∆PG30-0) (B), Matsuda Insulin Sensitivity IndexOGTT (C), total AUC glucose (D), incremental Cmax glucose (E) and absolute mean glucose (F). In the linear doseresponse graphs, the inner line represents the predicted linear trend, while the two outer lines represent the 95% CIs. In the non-linear dose-response graphs, the center line represents the mean, while the two outer lines represent the 95% CIs. P-values correspond to log-transformed data due to non-normal distribution of residuals for (A), (B), and (C). P-values were considered significant if P<0.0125, see Section 2.8. . A) Effect of small doses (5g and 10g) of fructose on incremental change for plasma glucose and the primary outcome of incremental area under the curve (iAUC) for plasma glucose following consumption of 75g-OGTT (assigned 0g fructose control), 75g-OGTT + 5g fructose and 75g-OGTT + 10g fructose in 25 healthy participants. B) Effect of small doses (5g and 10g) of allulose on incremental change in plasma glucose and the primary outcome of incremental area under the curve (iAUC) for plasma glucose following consumption of 75g-OGTT (assigned 0g allulose control), 75g-OGTT + 5g allulose and 75g-OGTT + 10g allulose in 25 healthy participants. Data reported as mean + SEM. *P-values <0.05 are considered significant, see Section 2.8. Note that 5-10g of fructose is 1-2% of total daily calories and allulose given at doses of 5-10g contributes 0.05-0.1% of total daily calories in a 2000kcal diet. Figure S12. A) Effect of small doses (5g and 10g) of fructose on the secondary outcomes of incremental change and incremental area under the curve (iAUC) for plasma insulin following consumption of 75g-OGTT (assigned 0g fructose control), 75g-OGTT + 5g fructose and 75g-OGTT + 10g fructose in 25 healthy participants. B) Effect of small doses (5g and 10g) of allulose on the secondary outcomes of incremental change and incremental area under the curve (iAUC) for plasma insulin following consumption of 75g-OGTT (assigned 0g allulose control), 75g-OGTT + 5g allulose and 75g-OGTT + 10g allulose in 25 healthy participants. Data reported as mean + SEM. Note that all p-values are from log-transformed data due to non-normality of residuals. P-values <0.0125 are considered significant, see Section 2.8. *Pvalue was rounded down from p=0.014 and is not considered significant. Note that 5-10g of fructose is 1-2% of total daily calories and allulose given at doses of 5-10g contributes 0.05-0.1% of total daily calories in a 2000kcal diet. Figure S13 . A) Linear (left) and non-linear dose-response (right) analysis of the effect of small doses of fructose on plasma glucose iAUC in a sensitivity analysis using the assigned fructose control. B) Linear (left) and non-linear (right) dose-response analysis of the effect of small doses of allulose on plasma glucose iAUC in a sensitivity analysis using the assigned allulose control. In the linear dose-response graphs, the middle black line represents the predicted linear trend, while the two grey lines represent the 95% CIs. In the non-linear dose-response graphs, the middle black line represents the mean, while the two grey lines represent the 95% CIs. P-values were considered significant if P<0.0125, see Section 2.8. Figure S14 . Linear (left) and non-linear (right) dose-response analysis of the effect of small doses of fructose on absolute Cmax glucose (A), Tmax glucose (B), mean incremental glucose (C), insulin iAUC (D), absolute Cmax insulin (E) and Tmax insulin (F). This sensitivity analysis used the assigned fructose 0g-control in the dose response analysis. In the linear dose-response graphs, the middle black line represents the predicted linear trend, while the two outer lines represent the 95% CIs. In the non-linear dose-response graphs, the middle black line represents the mean, while the two outer lines represent the 95% CIs. P-values correspond to logtransformed data due to non-normal distribution of residuals for (D) and (E). *P-values <0.05 are considered significant, see Section 2.8. . This sensitivity analysis used the assigned fructose 0g-control in the dose response analysis. In the linear dose-response graphs, the inner line represents the predicted linear trend, while the two outer lines represent the 95% CIs. In the non-linear dose-response graphs, the center line represents the mean, while the two outer lines represent the 95% CIs. P-values correspond to log-transformed data due to non-normal distribution of residuals for (A), (B), and (C). P-values <0.05 are considered significant, see Section 2.8. Figure S16 . Linear (left) and non-linear (right) dose-response analysis of the effect of small doses of fructose on total AUC insulin (A), incremental Cmax insulin (B), absolute mean insulin (C) and Insulin Secretion-Sensitivity Index-2 (ISSI-2) (D). This sensitivity analysis used the assigned fructose 0g-control in the dose response analysis. In the linear dose-response graphs, the inner line represents the predicted linear trend, while the two outer lines represent the 95% CIs. In the non-linear dose-response graphs, the center line represents the mean, while the two outer lines represent the 95% CIs. P-values correspond to log-transformed data due to non-normal distribution of residuals for (A), (B), (C), and (D). P-values <0.05 are considered significant, see Section 2.8. . This sensitivity analysis used the assigned allulose 0g-control in the dose response analysis. In the linear dose-response graphs, the middle black line represents the predicted linear trend, while the two outer lines represent the 95% CIs. In the non-linear dose-response graphs, the middle black line represents the mean, while the two grey lines represent the 95% CIs. P-values correspond to log-transformed data due to non-normal distribution of residuals for (D) and (E). P-values <0.05 are considered significant, see Section 2.8. Figure S18 . Linear (left) and non-linear (right) dose-response analysis of the effect of small doses of allulose on mean incremental insulin (A), Early Insulin Secretion Index (∆PI30-0/∆PG30-0) (B), Matsuda Insulin Sensitivity IndexOGTT (C), total AUC glucose (D), incremental Cmax glucose (E) and absolute mean glucose (F). This sensitivity analysis used the assigned allulose 0g-control in the dose response analysis. In the linear dose-response graphs, the middle black line represents the predicted linear trend, while the two grey lines represent the 95% CIs. In the non-linear dose-response graphs, the middle black line represents the mean, while the two outer lines represent the 95% CIs. P-values correspond to log-transformed data due to non-normal distribution of residuals for (A), (B), and (C). P-values <0.05 are considered significant, see Section 2.8. Figure S19 . Linear (left) and non-linear (right) dose-response analysis of the effect of small doses of allulose on total AUC insulin (A), incremental Cmax insulin (B), absolute mean insulin (C) and Insulin Secretion-Sensitivity Index-2 (ISSI-2) (D). This sensitivity analysis used the assigned allulose 0g-control in the dose response analysis. In the linear dose-response graphs, the middle black line represents the predicted linear trend, while the two grey lines represent the 95% CIs. In the non-linear dose-response graphs, the middle black line represents the mean, while the two outer lines represent the 95% CIs. P-values correspond to log-transformed data due to non-normal distribution of residuals for (A), (B),(C) and (D). P-values <0.05 are considered significant, see Section 2.8. Figure S20 . Equivalence test comparing the effect of allulose to fructose on plasma glucose iAUC. % difference plasma glucose iAUC = [(alluloseiAUCglucose/controliAUCglucose) -(fructoseiAUCglucose/controliAUCglucose)] x 100%. The assigned 0g fructose and 0g allulose controls were used for this analysis. The dotted lines represent the ± 20% equivalence margins. The red diamond represents the mean difference and the black line crossing through the diamond represents the 90% CI. CI, confidence interval; iAUC, incremental area under the curve.
